The results of this exploratory study showed that testicular cancer survivors (TCS) previously treated with chemotherapy have an immunological phenotype associated with immunosenescence and increased expression of the aging biomarker p16INK4a in CD3+ lymphocytes. This evidence concerns the gene CDKN2A and testicular cancer.